Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab.
Novartis and the non-profit Medicines for Malaria Venture (MMV) have advanced a novel drug combination for malaria into a phase 3 programme, raising hopes of a regimen that could be used to
Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to ac
Following the launch of LifeArc’s £100 million programme, Chronic Respiratory Infection Translational Challenge (CRI TC) – for the acceleration of the development of new clinical solutions
Cambridge, Massachusetts-based FogPharma has closed another impressive fundraising round, adding $178 million to the pot as it ushers its polypeptide-based drug candidates towards the clini
Germany's Merck KGaA has said it needs to double the productivity of its R&D operations, with the aim of launching a new product every 18 months on average, to boost its pharma business